日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft-Versus-Host Disease

阿沙替利单抗在慢性移植物抗宿主病患者中的免疫原性和临床意义

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.70161
Yang, Yan-Ou; Liu, Xing; Barker, Breann; Zhang, Xuecheng; Ordentlich, Peter
免疫/内分泌
发表日期：2026
文献求助 收藏

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

肾功能和肝功能损害对齐鲁吉塞替药代动力学的影响

期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1002/bcp.70372
Yang, Yan-Ou; Fang, Yunlan; Wang, Phillip; Liu, Xiang; Getsy, Jay; Rockich, Kevin
发表日期：2026
文献求助 收藏

Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor-like kinase-2 (ALK2) inhibitor, in healthy participants

在健康受试者中评估激活素受体样激酶-2 (ALK2) 抑制剂 zilurgisertib 的临床心脏安全性

期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.1618
Yang, Yan-Ou; Yang, Hong; Liu, Xing; Gong, Xiaohua; Getsy, Jay; Rockich, Kevin
信号转导
ALK
发表日期：2026
文献求助 收藏

High-level ePVS was accompanied by an increase in kidney transplant failure risk: analysis based on the MIMIC-IV database

高水平的ePVS与肾移植失败风险增加相关：基于MIMIC-IV数据库的分析

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1574525
Zhou, Zhirong; Zhang, Lin; Zhang, Delin; Yang, Yan; Ou, Shuiping
发表日期：2025
文献求助 收藏

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease

阿沙替利单抗治疗慢性移植物抗宿主病患者的暴露-反应关系

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3731
Yang, Yan-Ou; Volkova, Alina; Sokolov, Victor; Liu, Xing; Leon, Cristina; Kosinsky, Yuri; Sheng, Jennifer; Chen, Xuejun
发表日期：2025
文献求助 收藏

Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease.

对健康受试者和实体瘤或慢性移植物抗宿主病患者进行阿沙替利单抗的半机制群体药代动力学/药效动力学建模

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3503
Yang Yan-Ou, Sokolov Victor, Volkova Alina, Liu Xing, Leon Cristina, Kosinsky Yuri, Barker Breann, Zhang Xuecheng, Ordentlich Peter, Sheng Jennifer, Chen Xuejun
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study

在健康日本男性受试者中评估阿沙替利单抗的安全性、耐受性、药代动力学和药效学：一项 1 期随机、双盲、剂量递增研究的结果

期刊:Clinical Drug Investigation
影响因子:2.7
doi:10.1007/s40261-025-01438-7
Haranaka, Miwa; Kinami, Kenzo; Yang, Yan-Ou; Li, Hongfei; Pratta, Michael; Suzukawa, Kazumi
发表日期：2025
文献求助 收藏

Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults

在健康成年人中进行的单次和多次递增剂量 1 期研究，探讨了 Zilurgisertib 在进食和空腹状态下的药代动力学。

期刊:European Journal of Drug Metabolism and Pharmacokinetics
影响因子:2.4
doi:10.1007/s13318-024-00926-z
Yang, Yan-Ou; Gong, Xiaohua; Getsy, Jay; Wang, Phillip; Liu, Xiang; Sheng, Jennifer; Chen, Xuejun; Rockich, Kevin
发表日期：2025
文献求助 收藏

Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2

发现新型吡唑并嘧啶类化合物作为高效、选择性强且口服生物利用度高的ALK2抑制剂

期刊:ACS Medicinal Chemistry Letters
影响因子:4
doi:10.1021/acsmedchemlett.2c00206
Nguyen, Minh H; Atasoylu, Onur; Wu, Liangxing; Kapilashrami, Kanishk; Pusey, Michelle; Gallagher, Karen; Lai, Cheng-Tsung; Zhao, Peng; Barbosa, Joseph; Liu, Kai; He, Chunhong; Zhang, Colin; Styduhar, Evan D; Witten, Michael R; Chen, Yaoyu; Lin, Luping; Yang, Yan-Ou; Covington, Maryanne; Diamond, Sharon; Yeleswaram, Swamy; Yao, Wenqing
ALK
发表日期：2022
文献求助 收藏